Drug
Semaglutide 14 MG [Rybelsus]
Semaglutide 14 MG [Rybelsus] is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_2
1
33%
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(3)
Detailed Status
Recruiting2
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 21 (33.3%)
Phase 42 (66.7%)
Trials by Status
not_yet_recruiting133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_4
Semaglutide Treatment for Hyperglycaemia After Renal Transplantation
NCT05702931
recruitingphase_4
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
NCT07254572
not_yet_recruitingphase_2
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
NCT06913023
Clinical Trials (3)
Showing 3 of 3 trials
NCT05702931Phase 4
Semaglutide Treatment for Hyperglycaemia After Renal Transplantation
NCT07254572Phase 4
Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes
NCT06913023Phase 2
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3